Fragment screening by biochemical assay. (Q53591810)

16 May 2018

title

Fragment screening by biochemical assay. (English)

1 reference

16 May 2018

author name string

John Barker

1

1 reference

16 May 2018

Steve Courtney

2

1 reference

16 May 2018

Thomas Hesterkamp

3

1 reference

16 May 2018

Dirk Ullmann

4

1 reference

16 May 2018

Mark Whittaker

5

1 reference

16 May 2018

language of work or name

English

0 references

publication date

1 August 2006

1 reference

16 May 2018

Expert Opinion on Drug Discovery

published in

1 reference

16 May 2018

volume

1

1 reference

16 May 2018

issue

3

1 reference

16 May 2018

page(s)

225-236

1 reference

16 May 2018

Fragment-Based Drug Discovery

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Fragment-based lead discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Molecular recognition: the fragment approach in lead generation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Fragment-based lead discovery: leads by design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Fragonomics: fragment-based drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Ligand efficiency: a useful metric for lead selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Library design for fragment based screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Is there a difference between leads and drugs? A historical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Molecular complexity and its impact on the probability of finding leads for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Applications of SHAPES screening in drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Fragment-based lead discovery using X-ray crystallography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

A ‘Rule of Three’ for fragment-based lead discovery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Pursuing the leadlikeness concept in pharmaceutical research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

A specific mechanism of nonspecific inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Effect of detergent on "promiscuous" inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Identification and Prediction of Promiscuous Aggregating Inhibitors among Known Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Theory and applications of NMR-based screening in pharmaceutical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Using NMR for ligand discovery and optimization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Competition STD NMR for the detection of high-affinity ligands and NMR-based screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Second-site NMR screening and linker design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

SOS-NMR: a saturation transfer NMR-based method for determining the structures of protein-ligand complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Discovering high-affinity ligands for proteins: SAR by NMR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

High-throughput nuclear magnetic resonance-based screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Structure-activity relationships by mass spectrometry: identification of novel MMP-3 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Discovery of novel PTP1b inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Making drugs on proteins: site-directed ligand discovery for fragment-based lead assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Optical biosensors in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Surface plasmon resonance thermodynamic and kinetic analysis as a strategic tool in drug design. Distinct ways for phosphopeptides to plug into Src- and Grb2 SH2 domains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

A structure-based strategy for discovery of small ligands binding to functionally unknown proteins: combination of in silico screening and surface plasmon resonance measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Chemical microarrays, fragment diversity, label-free imaging by plasmon resonance--a chemical genomics approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

High-throughput crystallography to enhance drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Discovery of potent inhibitors of dihydroneopterin aldolase using CrystaLEAD high-throughput X-ray crystallographic screening and structure-directed lead optimization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Comparison of Assay Technologies for a Nuclear Receptor Assay Screen Reveals Differences in the Sets of Identified Functional Antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Fluorescence readouts in HTS: no gain without pain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

New fluorescence techniques for high-throughput drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Highly sensitive fluorescence detection technology currently available for HTS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Experiences in implementing uHTS--cutting edge technology meets the real world

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

PRO_SELECT: combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective factor Xa inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

X-ray and spectrophotometric studies of the binding of proflavin to the S1 specificity pocket of human alpha-thrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Design and synthesis of novel inhibitors of gelatinase B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Substrate activity screening: a fragment-based method for the rapid identification of nonpeptidic protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Tyrosylprotein sulfotransferase inhibitors generated by combinatorial target-guided ligand assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Combinatorial target-guided ligand assembly: identification of potent subtype-selective c-Src inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

NanoStore: a concept for logistical improvements of compound handling in high-throughput screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.3.225

21 January 2018

Identifiers

DOI

10.1517/17460441.1.3.225

1 reference

16 May 2018

PubMed ID

23495844

1 reference

16 May 2018